The NCCN Guidelines for Kidney Cancer have undergone a major shift in the risk categorization used for designating “preferred” and “other recommended” or “useful under certain circumstances” first-line treatments. In the most recent version of the guidelines, “favorable risk” is now its own risk category and “intermediate risk” and “poor risk” are combined into one category. The treatment recommendations for clear cell renal cell carcinoma are continually revised and more new options are anticipated based on encouraging results from pivotal trials. In his presentation at the NCCN 2019 Annual Conference, Dr. Jonasch described these promising findings.
Correspondence: Eric Jonasch, MD, Department of Genitourinary Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1374, Houston, TX 77030. Email: email@example.com